NCT02304419View on ClinicalTrials.gov

A Study of Galunisertib on the Immune System in Participants With Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Neoplasm
Interventions
DRUG

Galunisertib

Administered orally.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02304419 - A Study of Galunisertib on the Immune System in Participants With Cancer | Biotech Hunter | Biotech Hunter